

**SUPPLEMENTARY TABLES**

**Supplementary Table 1. Significant changes in transcription levels of the proteasome 26S subunit, ATPase (PSMC) family genes in different types of breast cancer from the METABRIC database.**

Gene	Types of sarcoma vs. normal	<i>p</i> value (cancer/normal)	<i>t</i> -test (cancer/normal)	Multiple of change (cancer/normal)	% Gene ranking
<b>PSMC1</b>	Invasive ductal breast carcinoma	2.16E-45	17.213	1.239	1776 (in top 10%)
	Invasive lobular breast carcinoma	3.73E-15	8.299	1.186	2610 (in top 14%)
	Invasive ductal and invasive lobular breast carcinoma	2.32E-12	7.567	1.186	2619 (in top 14%)
	Tubular breast carcinoma	5.85E-10	6.657	1.156	3135 (in top 17%)
	Medullary breast carcinoma	6.09E-09	7.432	1.43	1189 (in top 7%)
	Invasive breast carcinoma	5.63E-04	3.76	1.249	2613 (in top 14%)
	Ductal breast carcinoma in situ	1.50E-02	2.516	1.13	4252 (in top 23%)
	Benign breast neoplasm	2.30E-02	3.543	1.172	1385 (in top 8%)
<b>PSMC2</b>	Invasive ductal breast carcinoma	1.37E-29	13.032	1.212	3117 (in top 17%)
	Tubular breast carcinoma	4.52E-10	6.731	1.206	3098 (in top 17%)
	Medullary breast carcinoma	2.74E-07	6.158	1.479	1898 (in top 10%)
	Invasive ductal and invasive lobular breast carcinoma	2.84E-07	5.278	1.189	4496 (in top 24%)
	Invasive lobular breast carcinoma	2.52E-04	3.521	1.08	6711 (in top 35%)
	Mucinous breast carcinoma	4.81E-04	3.453	1.11	5503 (in top 29%)
	Ductal breast carcinoma in situ	2.00E-03	3.814	1.224	1815 (in top 10%)
	Invasive breast carcinoma	1.10E-02	2.468	1.164	4963 (in top 26%)
<b>PSMC3</b>	Breast carcinoma	1.60E-02	2.378	1.149	4844 (in top 26%)
	Invasive ductal breast carcinoma	1.81E-56	21.593	1.391	1165 (in top 7%)
	Invasive lobular breast carcinoma	3.18E-21	10.223	1.268	1647 (in top 9%)
	Invasive ductal and invasive lobular breast carcinoma	1.18E-14	8.518	1.283	2072 (in top 11%)
	Tubular breast carcinoma	1.54E-10	6.928	1.213	2948 (in top 16%)
	Mucinous breast carcinoma	2.35E-09	6.759	1.251	2118 (in top 11%)
	Medullary breast carcinoma	5.08E-09	7.49	1.581	1167 (in top 7%)
	Invasive breast carcinoma	1.04E-05	5.336	1.334	995 (in top 6%)
<b>PSMC4</b>	Breast carcinoma	7.67E-04	3.846	1.207	2135 (in top 12%)
	Ductal breast carcinoma in situ	1.00E-03	3.932	1.328	1734 (in top 9%)
	Invasive ductal breast carcinoma	1.28E-53	20.067	1.663	1299 (in top 7%)
	Invasive lobular breast carcinoma	4.00E-21	10.233	1.505	1665 (in top 9%)
	Invasive ductal and invasive lobular breast carcinoma	8.95E-21	10.973	1.704	1064 (in top 6%)
	Mucinous breast carcinoma	3.44E-20	12.783	1.953	138 (in top 1%)
	Tubular breast carcinoma	2.41E-11	7.464	1.468	2693 (in top 14%)
	Breast carcinoma	9.68E-06	6.234	1.766	501 (in top 3%)
<b>PSMC5</b>	Ductal breast carcinoma in situ	7.54E-05	5.948	1.877	375 (in top 2%)
	Invasive breast carcinoma	2.24E-04	4.167	2.021	2119 (in top 11%)
	Medullary breast carcinoma	1.00E-03	3.259	1.381	4759 (in top 25%)
	Benign breast neoplasm	1.60E-02	5.134	2.085	1096 (in top 6%)
	Breast phyllodes tumor	1.80E-02	3.029	1.637	2003 (in top 11%)
	Invasive ductal breast carcinoma	7.02E-36	15.397	1.431	2506 (in top 14%)
	Invasive lobular breast carcinoma	6.11E-13	7.435	1.274	3086 (in top 17%)
	Tubular breast carcinoma	3.05E-12	7.714	1.403	2414 (in top 13%)
<b>PSMC6</b>	Invasive ductal and invasive lobular breast carcinoma	5.95E-12	7.294	1.327	2733 (in top 15%)
	Mucinous breast carcinoma	1.09E-09	6.884	1.393	1996 (in top 11%)
	Invasive breast carcinoma	7.93E-06	5.41	1.518	916 (in top 5%)
	Medullary breast carcinoma	5.07E-04	3.559	1.273	4293 (in top 23%)
	Ductal breast carcinoma in situ	2.00E-03	3.797	1.493	1893 (in top 10%)
	Breast carcinoma	8.00E-03	2.758	1.317	4011 (in top 21%)
	Benign breast neoplasm	4.10E-02	3.005	1.297	2135 (in top 12%)
	Invasive ductal breast carcinoma	9.03E-12	6.909	1.065	5885 (in top 31%)
<b>PSMC6</b>	Tubular breast carcinoma	1.96E-07	5.569	1.173	4195 (in top 22%)
	Invasive ductal and invasive lobular breast carcinoma	6.40E-04	3.303	1.14	6817 (in top 36%)
	Invasive lobular breast carcinoma	3.00E-03	2.815	1.052	7600 (in top 40%)
	Mucinous breast carcinoma	4.00E-03	2.76	1.05	6596 (in top 35%)
	Breast carcinoma	7.00E-03	2.771	1.061	3885 (in top 21%)
Ductal breast carcinoma in situ	3.90E-02	1.965	1.068	5699 (in top 30%)	

**Supplementary Table 2. Pathway analysis of genes co-expressed with proteasome 26S subunit, ATPase (PSMC) family genes from public breast cancer databases using the MetaCore database (with  $p < 0.01$  set as the cutoff value).**

#	Map	p Value	Network objects from active data
1	Cytoskeleton remodeling_Regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases	6.29E-07	ARPC1B, BETA-PIX, Talin, Vinculin, ERM proteins, MyHC, DMPK, Spectrin, MLCK, MRLC, Rac1-related
2	Cell cycle_Chromosome condensation in prometaphase	1.24E-06	CAP-G, Cyclin A, CAP-G/G2, Aurora-A, Cyclin B, Histone H3, CDK1 (p34)
3	Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins	1.32E-06	Importin (karyopherin)-alpha, Cyclin A, Cyclin D1, Cyclin D3, Cyclin D, CDK1 (p34)
4	Transcription_Role of heterochromatin protein 1 (HP1) family in transcriptional silencing	1.48E-06	SUMO-1, Cyclin A2, HDAC4, Rb protein, MEF2, Histone H4, HDAC5, Histone H3, CDK1 (p34)
5	Cell cycle_Role of APC in cell cycle regulation	2.43E-06	Geminin, Cyclin A, Aurora-A, Kid, Cyclin B, MAD2a, Securin, CDK1 (p34)
6	Cell cycle_Spindle assembly and chromosome separation	3.13E-06	Importin (karyopherin)-alpha, Aurora-A, HEC, Kid, Cyclin B, MAD2a, Securin, CDK1 (p34)
7	Cell cycle_Regulation of G1/S transition (part 1)	9.74E-06	Cyclin A, Skp2/TrCP/FBXW, Cyclin D1, TGF-beta receptor type II, RING-box protein 1, SMAD4, Cyclin D3, Cyclin D
8	Cell cycle_Regulation of G1/S transition (part 2)	1.06E-05	Cyclin A2, Cyclin A, Cyclin D1, Rb protein, Cyclin D3, Cyclin D, c-Fos
9	Abnormalities in cell cycle in SCLC	1.36E-05	PCNA, Cyclin A, Cyclin D1, Rb protein, Histone H3, CDK1 (p34), Cyclin E2
10	Prolactin/JAK2 signaling in breast cancer	4.63E-05	Bcl-6, STAT5, Cyclin D1, STAT5B, PKM2, Cyclophilin A
11	Ubiquinone metabolism	4.65E-05	NDUFAB1, NDUFA4, NDUFB6, NDUFA2, NDUFA11, coenzyme Q2 homolog, prenyltransferase (yeast), NDUFB5, NDUFB10, NDUFC1, NDUFV3
12	Cell cycle_The metaphase checkpoint	6.12E-05	SPBC25, Aurora-A, HEC, CDCA1, HZWint-1, MAD2a, CENP-H
13	Transport_The role of AVP in regulation of Aquaporin 2 and renal water reabsorption	7.92E-05	MRLC2, MyHC, SNAP-23, Annexin II, VAMP2, MLCK, MRLC, c-Fos
14	Immune response_Function of MEF2 in T lymphocytes	7.92E-05	MAP3K3, MEF2D, HDAC4, Calcineurin A (catalytic), MEF2, HDAC5, MEF2C, Calcineurin A (beta)
15	Cell cycle progression in Prostate Cancer	1.05E-04	Beta-catenin, Cyclin D1, STAT5B, Rb protein, Cyclin B, CDK1 (p34), c-Fos
16	Immune response_ETV3 effect on CSF1-promoted macrophage differentiation	1.57E-04	MSK1/2 (RPS6KA5/4), ETV3, PRIM2A, HDAC5, CDK1 (p34)
17	Angiotensin II Signaling in Cardiac Hypertrophy	2.05E-04	Thioredoxin, CBP, HDAC4, Calcineurin A (catalytic), NF-kB, HDAC5, SOD1, TRPC1, c-Fos
18	Cell cycle_Cell cycle (generic schema)	2.63E-04	Cyclin A, Rb protein, Cyclin B, Cyclin D, CDK1 (p34)
19	Signal transduction_Activin A signaling regulation	3.07E-04	CBP, Histone H2, SMAD4, TGF-beta receptor type III (betaglycan), Histone H4, Histone H3
20	Aminoglycoside- and cisplatin-induced hair cell death	3.65E-04	Calpain 1(mu), Cytochrome c, Beta-catenin, Histone H2A, HDAC4, Calcineurin A (catalytic), Histone H2B, Histone H4, NF-kB, Histone H3, c-Fos
21	Cell cycle_Sister chromatid cohesion	4.14E-04	PCNA, Cyclin B, Securin, Histone H3, CDK1 (p34)
22	Noise-induced hair cell death and spiral ganglion neuron degeneration	4.18E-04	Calpain 1(mu), Cytochrome c, Alpha-fodrin, VAMP1, GDNF, ERM proteins, HDAC4, Rb protein, Calcineurin A (catalytic), Histone H3
23	Cell cycle_ESR1 regulation of G1/S transition	4.28E-04	Cyclin A2, Cyclin A, Skp2/TrCP/FBXW, Cyclin D1, Rb protein, c-Fos
24	Transcription_N-CoR/SMRT complex-mediated epigenetic gene silencing	4.58E-04	PBX1, HDAC4, Histone H2B, Histone H4, NF-kB, HDAC5, c-Fos
25	HBV-dependent transcription regulation leading to HCC	6.24E-04	PCNA, CBP, EGR2 (Krox20), Cyclin D1, Pin1
26	Development_Role of HDAC and calcium/calmodulin-dependent kinase (CaMK) in control of skeletal myogenesis	7.45E-04	MAP3K3, MEF2D, HDAC4, Calcineurin A (catalytic), MEF2, HDAC5, MEF2C
27	CREB1-dependent transcription deregulation in Huntington's Disease	7.55E-04	Cytochrome c, CBP, NDUFB5, COX VIa-1, SOD1
28	Development_NOTCH1-mediated pathway for NF-KB activity modulation	7.55E-04	Jagged1, MAML1, Histone H4, NF-kB, Histone H3
29	Apoptosis and survival_Ubiquitination and phosphorylation in TNF-alpha-induced NF-kB signaling	7.81E-04	UEV1A, MAP3K3, E2N(UBC13), TRADD, NF-kB1 (p105), NF-kB1 (p50)
30	Mitogenic action of ErbB2 in breast cancer	1.04E-03	Beta-catenin, Cyclin G2, Cyclin D1, MSK1, ErbB4, NF-kB, c-Fos